Photocure ASA - Photocure's partner Ipsen announces 4Q11 Hexvix® sales in Germany and Italy

Published: 2 February 2012Financial Investment & StockPartnership News & Expansion


Oslo, Norway, February 2, 2012: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces that its strategic partner, Ipsen, has announced the 4Q 2011 sales results of Hexvix for Germany and Italy. Ipsen initiated commercialization in these two markets in November 2011. The announcement from Ipsen is available on

Photocure will present its 4Q2011 and full year 2011 results on February 16, 2012. 

Ipsen, a leader in Uro-Oncology, is Photocure's new strategic partner for commercialising Hexvix, the flagship brand to aid in diagnosing bladder cancer. In the new partnership, announced on September 27, 2011, Ipsen will be responsible for marketing and selling Hexvix worldwide, excluding the US and Nordic region. Ipsen has a strong and well established uro-oncology franchise and will commercialize Hexvix through its dedicated urology sales force. In November 2011 Ipsen initiated commercialization in Germany and Italy and will commence in the remainder of the markets in their territory in 2012.

For further information, please contact:

President & CEO Kjetil Hestdal
Tel: + 47 913 19 535, Email:

M: Communications
Mary Clark, Amber Bielecka, Hollie Vile
Tel: +44 207920 2361, Email:

About Photocure ASA
Photocure ASA is a worldwide leader in photodynamic technology. Listed on the Oslo Stock Exchange (OSE: PHO), Photocure is focused on photodynamic technologies in dermatology and cancer. The company strives to solve unmet needs by developing new and innovative solutions based on its patented Photocure Technology(TM). Photocure markets and sells its own products in selected markets and has developed strong partnerships with leading pharmaceutical companies on a regional and global basis. Photocure's bladder cancer diagnostic product, Cysview/Hexvix is approved in Europe and the US. In addition, the company markets Allumera®, a photodynamic cosmetic in the US. Setting new standards for diagnosis and treatment of several different conditions, Photocure Technology(TM) is continuously being tested for new products and applications in cancer and dermatology.

Visonac®, Allumera®, Photocure® and Cysview®/Hexvix® are registered trademarks of Photocure ASA. For more information about Photocure, visit

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

News and events